MENLO PARK, Calif., October 7, 2019 \u2013 GRAIL, Inc., a healthcare company whose mission is to detect cancer early, when it can be cured, today announced that Matthew P. Young has been appointed Chief Operating Officer and Chief Financial Officer effective October 28, 2019.<\/p>\n
\u201cMatt is a seasoned, strategic business partner who brings more than two decades of leadership experience to further strengthen our ability to accelerate our multi-cancer early detection test toward commercialization,\u201d said Hans Bishop, Chief Executive Officer at GRAIL. \u201cGRAIL will be well served by Matt\u2019s significant industry experience in finance and operations, and we are excited to welcome him to GRAIL.\u201d<\/p>\n
\u201cI\u2019m thrilled to be joining a company that is strongly positioned to leverage the intersection of healthcare and technology and take on the challenge of detecting cancer early,\u201d said Mr. Young. \u201cI look forward to joining the GRAIL team and working together to make a transformational impact on the future of cancer care.\u201d<\/p>\n
Mr. Young joins GRAIL from Jazz Pharmaceuticals, a biopharmaceutical company, where he most recently served as the company\u2019s Executive Vice President and Chief Financial Officer. Prior to Jazz Pharmaceuticals, Mr. Young worked in investment banking for approximately 20 years in positions at Barclays Capital Inc., Citigroup Global Markets Inc., and Lehman Brothers Inc. Currently, he sits on the board of PRA Health Sciences, Inc., where he serves on the compensation and audit committee. He also serves as Lead Independent Director and Chairman of the audit committee of CytomX Therapeutics, Inc., a biopharmaceutical company. Mr. Young earned his bachelor\u2019s degree in Economics and an M.B.A. from the Wharton School of the University of Pennsylvania.<\/p>\n